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Figure 1. Challenges and strengths of MarketScan administrative data for HCT research
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tions to ensure valid results and accurate measures of
quality, costs and resource utilization. A thorough
understanding of strengths and weaknesses of claims data
are necessary in order to minimize bias and to select a
cohort that is most representative of the questions
that are being addressed. Cohort selection is presently
ongoing and additional challenges and solutions will be
discussed.525
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Background: Stem cell transplantation (SCT) is an incred-
ibly stressful and demanding experience for pediatric pa-
tients, as well as their family members. Historically, families
of pediatric patients undergoing SCT did not meet with the
psychosocial team until after admission. As a result, the
provision of psychoeducation regarding the manner in
which the SCT may psychologically and ﬁnancially impact
the patient and family members is delayed. More specif-
ically, individual, caregiver, or family-based interventions to
address issues such as procedural anxiety, mood dysregu-
lation associated with diagnosis and treatment, and signif-
icant stress related to treatment decision-making are
unavailable to families prior to their inpatient admission.
Aim: This quality improvement project proposed the intro-
duction of a standardized pre-admission psychosocial
assessment for pediatric stem cell transplant families.Goals: The psychosocial assessment process will be more
efﬁcient.
The SCT care team will acquire information about each
family’s individualized psychosocial needs earlier.
Emotional and resource related support will be available
to patients and families earlier, which will allow for the
provision of support around pre-admission stressors and
more preparation for post-admission stressors.
Patient population: Allogeneic stem cell transplant patients
referred from outside institutions.
Patients receiving stem cell transplantation for metabolic
diseases.
Patients receiving gene therapy.
Interventions: Pediatric SCT clinicians and staff were sur-
veyed on their thoughts towards pre-admission psychosocial
assessments.
Project leaders met with SCT patient coordinators to
deﬁne patient selection criteria and develop the scheduling
process.
Psychosocial clinician started to attend weekly Patient
Review Meeting.
Psychosocial evaluation added to Transplant Pre-Admis-
sion Checklist.
Conclusions:Met and exceeded the goal of evaluating 50% of
the deﬁned patient population.
Early psychosocial intervention is necessary and valuable.
Continued data gathering is warranted to further assess
the effectiveness of the interventions.
Outcome measures are needed to determine the projects
impact on patient care.
Next Steps: This project is ongoing at time of submission.
The new process will be reviewed at six months and twelve
months post implementation. Stakeholders will be resur-
veyed to determine the necessity and value of a pre-admis-
sion psychosocial assessment. Outcome measures will be
developed to determine overall patient satisfaction. Moni-
toring of clinician and coordinator burden will continue. We
are currently surveying other SCT programs on psychosocial
services offered; we have contacted 89 centers and have a
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we hope to offer a pre-admission psychosocial evaluation to
the entire pediatric SCT population.526
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Timely administration of antibiotics in highly immunocom-
promised patients presenting to the emergency room with
neutropenic fever reduces hospital stays, mortality due to
sepsis, and costs. Current guidelines recommend that he-
modynamically unstable patients receive broad-spectrum
antibiotics within 30 minutes of arrival to the Emergency
Department. For hemodynamically stable patients, this in-
terval increases to one hour. As a community hospital
launching a new blood and marrow transplant program, it
was imperative that the Emergency Department and
Oncology staff follow best practice in managing neutropenic
fever.
The transplant team, the Emergency Department, and nurse
educators were enlisted to ensure that the ED physicians, ED
triage nurses, hospitalists, critical care physicians and ICU
nurses, and the new BMT/Oncology unit nurses recognized
the unique concerns related to managing complex hemato-
logic malignancy and blood and marrow transplant patients.
The Very Immune Compromised Patient Alert (VIP) protocol
was implemented. The VIP Program consists of patient and
family education, a VIP card that is presented at the ED, ED
staff education, and a rapid triage and intervention protocol.
Departments impacted by the new protocol, including Lab-
oratory, Microbiology and Radiology received additional
training. The protocol for high-risk patients presenting to the
Emergency Department with neutropenic fever was set into
place in December 2013 two months before the ﬁrst patient
scheduled for transplant.
Post-implementation data for 23 patients demonstrated a
median door to antibiotic time of 52 minutes (range 27e107
minutes).
Next steps: Continue to investigate barriers to rapid
deployment of this protocol in febrile neutropenic patients.
Develop and implement strategies for improvement in
diagnosis and ﬁrst dose of empirical therapy.
Continue to track datawith each VIP patient presenting to
the ED and report to Cancer Committee and Quality Council
quarterly.527
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day readmission rate for BMT patients. Our program has
been active in attempting to reduce the 30 day readmission
rate since 2011. Initial reported metrics were available at the
Cancer Center level. Initiatives were undertaken to drill
down to only BMT readmissions enabling us to ascertain a
relevant rate for our program.
Methods: Data from 2009 & 2010 were analyzed to deter-
mine the 30 day readmission base rate. Data was categorized
according to autologous, allogeneic inpatient and allogeneic
outpatient transplants. Only readmissions occurring after
index transplant hospitalization were included. Also
included were readmissions to other services (ICU, leukemia
unit etc.). 30 day readmission numbers (numerator) were
easily obtained through a hospital quality outcomes data-
base; however, determining the denominator necessitated a
manual analysis from 2 years’ worth of weekly meeting mi-
nutes. Readmission rates were monitored monthly at the
BMT Quality Assurance meeting. We have experienced many
limitations in calculating and maintaining readmission rates
including:
Data pulled from the BMT database for monthly reporting
proved prohibitive due to time needed to clean up data.
Different reporting platforms at the hospital level for both
discharges and readmissions.
Time lag in data availability for discharged patients from
the hospital database.
Gaps in data posting to hospital database, results in
multiple data pulls.
Necessity to reconcile/double check data monthly.
There are many variables to consider when determining
which readmissions/discharges to include (small changes in
either category can reﬂect a large change in rate):
Pre transplant admit/discharge within 30 days of trans-
plant admission (eg, BMT admit within 30 days of discharge
after leukemia induction therapy).
Hospital metrics are unit based and may not include BMT
patients cared for outside the BMT unit.
ED admits.
Admissions for Observation only.
Admission/discharge from an outside hospital.
Weighing the difference between the hospital calculated
readmission rate and that which is beneﬁcial from a BMT
quality/patient safety perspective.
Fields analyzed monthly include: number of days be-
tween admissions, readmission length of stay (LOS), index
admission LOS; readmission reason, comorbidity score,
location admitted from etc., we are always attempting to
identify a focal point to direct efforts to reduce the read-
mission rate.
Conclusion: Determine which calculation factors are most
meaningful for your BMT program. Develop a system which
is easy to maintain on a routine basis and in as real-time as
possible. Engage as many disciplines within your program to
contribute input for readmission impact projects. Resolve the
fact that it may be necessary to sustain a hospital metric and
a BMT metric.528
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